رادار التجارب السريرية

Any indication for dual antiplatelet therapy, including

• Acute/recent (within 1 year) ACS (NSTE-ACS or STEMI)
• Recent PCI requiring continuation of dual antiplatelet therapy after CABG

Current or anticipated use of oral anticoagulation;

Paroxysmal, persistent or permanent atrial fibrillation;

Any concomitant cardiac or non-cardiac procedure;

Planned cardiac or non-cardiac surgery within one year;

Preoperative end-organ dysfunction (dialysis, moderate to severe liver failure, respiratory failure), cancer or other non-cardiac comorbidity with a life expectancy <5 years;

Inability to use the saphenous vein;

Contraindications to the use of aspirin;

Contraindications to the use of ticagrelor, including

• Known hypersensitivity to ticagrelor
• Active pathological bleeding (including, but not limited to gastrointestinal or intracranial bleeding)
• History of intracranial hemorrhage
• Concomitant therapy with strong CYP3A4 inhibitors (eg ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir)

Inability to undergo coronary computed tomographic angiography (CCTA);

Participating in another investigational device or drug study;

Women of childbearing potential

Any major perioperative complication including, but not limited to, stroke, TIA, MI, CABG-related bleeding (BARC type 4), sepsis.